Drug Profile

Teriparatide injection - Asahi Kasei Pharma

Alternative Names: hPTH - Asahi Kasei Pharma; MN-10-T; PTH injection - Asahi Kasei Pharma; Teribone

Latest Information Update: 25 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Asahi Kasei Pharma Corp
Developer Asahi Kasei Pharma Corp; Dong-A ST; MAIA Pharmaceuticals
Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
Mechanism of Action Parathyroid hormone replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Osteoporosis

Most Recent Events

19 Feb 2026 Teriparatide injection licensed to MAIA Pharmaceuticals for Osteoporosis in US
19 Feb 2026 Early research in Osteoporosis in USA (SC)
21 Oct 2025 Asahi Kasei has patent protection for Teriparatide injection in Japan

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com